AI Drug Discovery for Pharma and Biotech

RARE DISEASE

Malignant peripheral nerve sheath tumor

Synonyms: MPNST, Malignant neurilemmoma, Malignant neurofibroma, Malignant schwannoma, Neurofibrosarcoma, Neurogenic sarcoma

Drug discovery

drug

With orphan designation

Overview

Malignant peripheral nerve sheath tumor (MPNST) is a rare, aggressive soft tissue sarcoma arising from peripheral nerve sheaths, often linked to neurofibromatosis type 1 (NF1) or prior radiation [1][8][14]. Characterized by rapid growth, high recurrence rates (~40%), and frequent metastasis (commonly to lungs), it has a poor prognosis (5-year survival: 30-50%) [3][12][16]. Diagnosis relies on imaging (MRI/CT) and biopsy, while treatment emphasizes surgical resection with adjuvant radiotherapy; chemotherapy offers limited benefit in advanced disease [7][19][20].

Population

Annual incidence of 1.0-1.26 per million; 50% associated with NF1 (lifetime risk: 8-13%) [1][14][16].
Highest incidence in Black individuals vs. White/Asian groups; median diagnosis age 30-50 [2][6][12].
Gender distribution varies (slight male predominance in some studies, female in others) [2][14][18].

Burden

5-year survival <50%, dropping to <20% with metastasis [12][16][20].
~40-60% develop metastases; functional deficits common post-resection [3][8][20].
Non-White populations experience inferior survival independent of socioeconomic factors [10][18].

Therapies

Surgery: En bloc resection with negative margins (gold standard) [3][7][19].
Radiation: Neoadjuvant/adjuvant therapy to reduce local recurrence [7][20].
Chemotherapy: Anthracycline-based regimens (e.g., doxorubicin/ifosfamide) for metastatic disease; limited response rates (15-20%) [3][11][20].

Categories: rare neoplastic diseases, rare neurological diseases

Research Papers

998 drug discovery papers related to Malignant peripheral nerve sheath tumor, with 4 first-in-class and 16 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-06-18 | Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.

Neurofibromatosis Type 1 (NF1) predisposes to peripheral nerve tumor development. The progression from a benign plexiform neurofibroma (PNF) towards a deadly malignant peripheral nerve sheath tumor (MPNST) is not completely understood but commonly involves the sequential loss of NF1, CDKN2A, and polycomb repressive complex 2 (PRC2). Here we use an iPSC-derived neural crest (NC) model to reproduce this malignant transformation through gene editing. NF1-CDKN2A double-knockout (2KO) NCs form neurofibroma-like tumors in vivo, requiring inactivation of p14ARF and p16INK4a. Additional PRC2 loss (3KO) disrupts pluripotency and induces mesenchymal stem cell-like features. 3KO NCs undergo global chromatin reorganization that prevents gliogenesis by SOX10 silencing and activates neuro-mesenchymal transcriptional programs recapitulating PNF-ANNUBP-MPNST progression. Upon nerve engraftment, 3KO NC spheres form MPNST-like tumors in vivo, mimicking an early-stage MPNST. Furthermore, we use the 3D NC spheroid models to discover drugs targeting MPNSTs through high-throughput screening of epigenetic compounds. Poly(ADP-ribose) polymerase inhibitors (PARPi) exhibit selective efficacy in PRC2-deficient NC spheroids and Olaparib-Selumetinib combination is well tolerated and significantly suppresses tumor growth in a human MPNST PDX mouse model.

Open article ↗

2026-06-04 | Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

Pyroptosis, a lytic and immunogenic form of cell death, holds broad therapeutic potential, yet its selective induction in specific cell populations remains a fundamental challenge. Loss of the NF1 tumor suppressor, one of the most frequent events across pediatric and adult cancers, elevates RAS-GTP and drives tumorigenesis through hyperactivated RAS signaling. Here we demonstrate that protein kinase Cδ (PKCδ) agonism selectively triggers pyroptosis in NF1-deficient cells by exploiting their dependency on KRAS. PKCδ directly phosphorylates KRAS at S39 and S181, inducing KRAS-GDP accumulation and driving endoplasmic reticulum translocation. The dually phosphorylated KRAS-GDP interacts with caspase-8 and competitively displaces inhibitory BCL2, promoting caspase-8/caspase-3/gasdermin-E-mediated pyroptosis. This vulnerability is conserved across multiple NF1-deficient tumor types, and PKC agonism suppresses NF1-deficient neurofibroma and malignant peripheral nerve sheath tumor growth in vivo . These findings establish the inactive KRAS-GDP as a functionally active signaling molecule and PKCδ agonism as a selective therapeutic strategy for NF1-deficient cancers.

Open article ↗

2026-06-18 | Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.

Open article ↗

2026-06-04 | Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

1 orphan drug designation for Malignant peripheral nerve sheath tumor.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5)	small molecules	FDA	2022-07-25	—	Tango Therapeutics

Malignant peripheral nerve sheath tumor

Malignant peripheral nerve sheath tumor

Malignant peripheral nerve sheath tumor

Overview

Population

Burden

Therapies

Categories: rare neoplastic diseases, rare neurological diseases

Research Papers

2026-06-18 | Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.

2026-06-04 | Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

2026-06-18 | Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities.

2026-06-04 | Selective Pyroptosis in NF1-Deficient Cells through PKCδ Agonism.

Drug Discovery Landscape

Updated: Aug 3, 2026